CD8A and neoplasm: Notably, the antitumor effect of CAN-2409 was abrogated upon depletion of CD8+ T cells and adoptive transfer of CD8+ T cells from CAN-2409–treated mice yielded antitumor immunity in naïve tumor–bearing mice (5–7), providing evidence of effective CD8+ T-cell–mediated vaccination against the tumor.